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Genomic architecture of inflammatory bowel disease in five
families with multiple affected individuals
Anna B Stittrich1, Justin Ashworth1, Mude Shi2, Max Robinson1, Denise Mauldin1, Mary E Brunkow1, Shameek Biswas3, Jin-Man Kim4,
Ki-Sun Kwon5, Jae U Jung2, David Galas6,7, Kyle Serikawa3, Richard H Duerr8,9, Stephen L Guthery10, Jacques Peschon3, Leroy Hood1,
Jared C Roach1,11 and Gustavo Glusman1,11
Currently, the best clinical predictor for inflammatory bowel disease (IBD) is family history. Over 163 sequence variants have been
associated with IBD in genome-wide association studies, but they have weak effects and explain only a fraction of the observed
heritability. It is expected that additional variants contribute to the genomic architecture of IBD, possibly including rare variants
with effect sizes larger than the identified common variants. Here we applied a family study design and sequenced 38 individuals
from five families, under the hypothesis that families with multiple IBD-affected individuals harbor one or more risk variants that
(i) are shared among affected family members, (ii) are rare and (iii) have substantial effect on disease development. Our analysis
revealed not only novel candidate risk variants but also high polygenic risk scores for common known risk variants in four out of the
five families. Functional analysis of our top novel variant in the remaining family, a rare missense mutation in the ubiquitin ligase
TRIM11, suggests that it leads to increased nuclear factor of kappa light chain enhancer in B-cells (NF-κB) signaling. We conclude
that an accumulation of common weak-effect variants accounts for the high incidence of IBD in most, but not all families we
analyzed and that a family study design can identify novel rare variants conferring risk for IBD with potentially large effect size, such
as the TRIM11 p.H414Y mutation.
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INTRODUCTION
Inflammatory bowel disease (IBD, [MIM 266600]) is a chronic
inflammatory condition of the gastrointestinal tract that affects
about 3.7 million people in the US and Europe and shows
increasing incidence in Asia.1,2 The two subtypes of IBD are
Crohn’s disease (CD) and ulcerative colitis (UC). CD is characterized
by discontinuous, transmural inflammation that can affect any
part of the gastrointestinal tract, whereas UC presents with
continuous inflammation that is usually restricted to the mucosa
of the large intestine.
The strongest known risk factor for IBD is having an affected
first-degree relative.3 Compared with the general population,
siblings of CD patients are at 20- to 35-fold increased risk for
developing CD, and siblings of UC patients are at 8- to 15-fold
increased risk.4 Overall, a family history positive for IBD is reported
by 5–16% of CD patients and 8–14% of UC patients.4–6 This implies
a strong genetic contribution that is indeed demonstrated by the
success of genome-wide association studies (GWAS). The most
recent meta-analysis of CD and UC GWAS identified and validated
163 IBD-associated loci with genome-wide significance by
combining data from a total of 75,000 cases and controls.7 Most
of the identified loci confer risk to both subtypes.7
GWAS identify associations with common variants (usually
45% minor allele frequency), which have small effect sizes.
Indeed, the highest odds ratio reported for a genetic variant
influencing IBD is 3.99 for a loss-of-function variant in NOD2
(p.L1007fs).8 Carrying one copy of this risk allele quadruples the
probability of developing CD from the population background
prevalence of a quarter of a percent to 1%. To estimate the
combined effect of multiple risk variants present in an individual's
genome, a polygenic risk score can be calculated.9 Owing to the
lack of knowledge about interactions between genetic variants
and between genes and environment, polygenic risk score models
typically assume independence among these factors. Accordingly,
polygenic risk scores are calculated by multiplying the odds ratios
of each risk allele that is present in a genome and taking the
natural log of the product.9 The predictive value of the polygenic
risk score, that is, the degree to which it explains the disease
variance between affecteds and unaffecteds, depends on the
genetic contribution to the disease and on the extent to which the
variants that have a role have been identified. For IBD, taking all
the 163 associated variants into account was reported to explain
13.6% of the disease variance for CD and 7.5% of the disease
variance for UC.7 This is only a fraction of the 50% CD heritability
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and 19% UC heritability, respectively, that were observed in twin
studies.10 We expect that additional genetic risk variants exist and
that their identification will improve the predictive value of the
polygenic risk score. Rare variants are not typically assessed by
GWAS and may contribute to the ‘missing heritability’.
We therefore analyzed five families with multiple (three to six)
IBD-affected family members to test the hypothesis that low
frequency variants (o3% allele frequency) are shared among
affected family members and contribute to disease risk with
intermediate to high effect sizes within these families.
MATERIALS AND METHODS
Description of cohort
We studied five American families of European descent (Figure 1). Families
1–3 were recruited at the University of Utah with informed consent
through study protocol #48821 approved by the IRB (Institutional Review
Board). Families 4 and 5 were recruited through IRB-approved study
protocol IRB0503185 at the University of Pittsburgh. Diagnosis of IBD was
based on established criteria and required appropriate symptoms,
exclusion of infections and objective evidence of inflammation on
endoscopy, histology and/or radiology.11 An overview of disease onset
and clinical features of the affected family members is provided in
Supplementary Table 1.
Whole-genome sequencing
DNA was extracted from blood samples. Paired-end library preparation,12
whole-genome sequencing (WGS), alignment to the reference genome
(NCBI human genome assembly build 37) and variant calling were
performed by Complete Genomics (Mountain View, CA, USA). The average
coverage was greater than 40× .
Identification of candidate variants
Each family was analyzed separately because we were expecting rare
family-specific risk variants, possibly in different genes in each family. To
identify candidate variants, we used the Ingenuity Variant Analysis
software (Qiagen, Hilden, Germany) and the Family Genomics toolkit.13
We evaluated population frequencies of variants using Kaviar, a software
program that estimates variant frequencies by taking into account a
variety of public data sources as well as non-public genome sequences
available from studies at the Institute for Systems Biology.14 The latest
update of Kaviar includes genetic data from 77,238 individuals, comprising
populations from around the world but with a bias for European-descent
populations. We filtered for single-nucleotide variants and small indels that
had Complete Genomics sequencing quality scores ⩾ 35, allele frequency
⩽ 3%, and a putative effect on gene function or activity, i.e., loss-of-
function, missense or splice site mutations, or variants that putatively affect
microRNA binding, promoter activity or enhancer activity. In addition, we
filtered for variants that affect genes that are known to be of relevance for
IBD in the Ingenuity Knowledge Base. These are (i) genes in a set of 292
genes directly connected to IBD, (ii) genes with interactions to any of these
292 genes or (iii) genes that have a connection with any of the 81
substances that have been related to IBD (e.g., IBD therapeutics).
Computation of polygenic risk score
We divided a set of 163 previously identified IBD risk loci and their
respective odds ratios7 into lists of 140 CD loci and 133 UC loci. One
hundred and ten loci confer risk to both IBD subtypes and were included in
both lists, but with IBD subtype-specific odds ratios. Because this set of loci
does not contain two of the three well-characterized CD-associated loss-of-
function variants in the NOD2 gene, we added these loci and calculated
odds ratios for all the three loci based on reported frequencies in cases and
controls in different European populations.15 Specifically, we used the
following odds ratios: p.R702W, 2.023; p.G908R, 3.500; p.L1007 fs; 4.255. To
calculate the polygenic risk score, we took the natural log of the product of
the odds ratios of each risk variant that is observed in an individual’s
genome, i.e., if a risk variant is homozygous, it is multiplied twice; if it is
heterozygous, it is multiplied once; and if it is absent, it does not contribute
to the risk score. As controls we used 1,096 ISB in-house WGS from non-IBD
family studies that were also sequenced by Complete Genomics. None of
the genomes were derived from a cancer sample.
Protein modeling
We modeled the functional impact of mutations in the PRY-SPRY domain
on TRIM protein folding and stability with the Rosetta software.16,17 As no
crystal structure for TRIM11 was available, we used the Protein Data Bank
template structure of the PRY-SPRY domain of TRIM20 (Protein Data Bank
ID 2WL1). For both wild-type and mutant proteins, we sampled
conformations 100 times using a Monte Carlo procedure to minimize the
estimated total free energy of protein folding. The change in free energy
upon mutation (ΔΔG) estimates the impact of the mutation on folding and
stability, with positive ΔΔG values indicating destabilization.
Reporter assays
Wild-type TRIM11 was mutated to TRIM11 p.H414Y using a site-directed
mutagenesis kit (Life Technologies, Carlsbad, CA, USA). HEK293T cells were
transfected with reporter plasmid that harbors firefly luciferase under the
control of (1) the promoter of nuclear factor of kappa light chain enhancer
in B-cells (NF-κB1) or (2) the interferon signaling response element from
the promoter of interferon-induced protein with tetratricopeptide repeats
1, in addition to TK-Renilla luciferase control plasmid, TANK-binding
Figure 1. Pedigrees of the IBD-affected families. IBD, inflammatory bowel disease.
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kinase-1 (TBK1)-expressing plasmid and wild-type or mutant TRIM11. At
24 h after transfection reporter luciferase activity was measured using the
Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA).
Immunostaining
Tissue samples from the intestine of a 5-month-old C57BL6 mouse were
fixed in 10% buffered formalin and embedded in paraffin. Four-
micrometer-thick sections from the paraffin blocks were used. After
deparaffinization and antigen retrieval by pressure cooker in 10mmol/l
sodium citrate buffer (pH 6.0) at full power for 4 min, tissue sections were
treated with 3% hydrogen peroxide for 10min. The primary antibody for
TRIM11 (1:100 dilution, rabbit polyclonal; Proteintech, Chicago, IL, USA) was
incubated for 30min followed by treatment with the EnVision-HRP reagent
(Dako, Carpinteria, CA, USA) for 30min. The slides were then sequentially
incubated with DAB chromogen for 5 min, counterstained with Meyer’s
hematoxylin and mounted for microscopy. All immunostaining steps were
carried out at room temperature.
RESULTS
Sequencing of five IBD families
We used WGS to analyze 38 individuals from five families
including 15 CD patients, eight UC patients and 15 unaffected
first-degree family members (Figure 1). Family 1 displays distant
relationship over 10 generations between the two branches of the
family that were analyzed. Four CD patients and one UC patient in
the family were analyzed. Disease status is not known for all
individuals in the older generations, but several additional family
members are suspected to have (had) IBD. In Family 2, individual
2-V-1 is related to 2-VII-1 over 10 generations but not to other
analyzed individuals of the family. In addition, three other
branches of the family were analyzed that are distantly related
to each other. Four family members have UC and one has CD.
Family 3 is a nuclear family with an UC-affected father and two
CD-affected children. Family 4 is a nuclear family with two
unaffected parents but five of six children diagnosed with CD.
Individual 4-III-1 was included in the study because she is the
oldest from her generation and has reached an age at which the
4-II generation had already developed CD. Family 5 is a nuclear
family with unaffected parents but three children diagnosed with
CD. In addition, the UC-affected uncle of the children (5-II-1) was
analyzed. Individual 5-III-1 was not available for analysis.
Identification of risk variants
We first identified risk regions within which to focus our search for
variants. Within family 1 and family 2, the affected family members
are distantly related, i.e., separated by many meioses. Following
our hypothesis that affected individuals in each family share risk
variants, we aimed to identify genetic segments that are identical
by descent among all affected family members. In pedigrees with
distantly related affecteds, this approach greatly reduces the
search space, and therefore the number of false-positive
candidates, because with each meiosis the probability of sharing
a segment that is not causing an ascertained phenotype, is
approximately halved. According to Thomas et al.,18 and taking
into account a recombination rate of 35.3 per meiosis,19 we
calculated for families 1 and 2 the probability of observing an
identical-by-descent segment shared by all affected family
members (excluding individual 2-V-1 owing to different ancestry).
The probabilities for shared segments are 0.07 and 0.01 in family 1
and 2, respectively, suggesting that no identical-by-descent
regions are expected other than causative segments in
these families. However, Inheritance State Consistency Analysis13
on the sequence data identified a 2.6 Mb (GRCh37 chr6:
80,111,322–82,671,825) and a 4.5 Mb (GRCh37 chr6: 43,216,439–
47,754,537) shared segment in family 1, spanning several genes as
well as a gene desert. In family 2, we did not identify a shared
segment.
We next identified candidate risk variants using the filter criteria
outlined in the Materials and Methods section. The 2.6 Mb shared
segment in family 1 encompasses a single gene, Keratin 19, and
did not have any candidate variants by our criteria, although
these criteria are likely to filter some regulatory variants. We
identified four candidate variants in the 4.5 Mb segment,
potentially affecting TJAP1, HSP90AB1, NFKBIE and RUNX2
(Table 1). By restricting the identity-by-descent analysis to CD
patients, i.e., excluding 1-VII-6, we identified an additional
candidate variant in TRERF1. We furthermore searched
genome-wide in all the five families for candidate variants. The
nuclear families 3, 4 and 5 as well as nuclear sub-branches of
families 1 and 2 share many segments, so focusing on identity by
descent represents much less of an advantage. Candidate variants
are summarized in Table 1.
Polygenic risk score analysis
In addition to the identification of new candidate risk variants, we
analyzed the families for the burden of known single-nucleotide
polymorphism associations with IBD. Using recent GWAS results
on 163 genome-wide significant associations and the respective
odds ratios,7 we calculated the UC and CD polygenic risk score for
each individual (see Materials and Methods). We used 1,096 WGS
controls available in-house at ISB from other family studies not
related to IBD (Figure 2a). The CD polygenic risk scores of familial
CD cases tend to be in the high range of scores compared with
controls, with a significantly higher mean score (P= 1.7e− 06,
Figure 2b). For familial UC cases, the mean UC polygenic risk score
did not differ significantly between cases and controls (P= 0.19).
To estimate the predictive value of the polygenic risk scores, we
used receiver operator characteristic analysis. The area under the
curve was 0.85 for discriminating CD cases from controls using the
CD polygenic risk score (Figure 2c). The UC polygenic risk score did
not perform as well and resulted in an area under the curve of
0.59. To determine how much of the variance between familial
cases and unrelated unaffected controls can be explained with the
respective polygenic risk scores, we used logistic regression and
calculated the Nagelkerke pseudo R2.9 The CD polygenic risk score
accounted for 39% of the variance between familial CD cases and
controls. The UC polygenic risk score accounted for just 1% of the
variance between familial UC cases and controls.
The unaffected family members in our study have only a slightly
increased CD polygenic risk score compared with controls
(P= 0.149); for UC, we do not detect a difference between
unaffected family members and controls (Figure 2d). This may
be owing to the small study size. If we assess only unaffected
parents of CD-affected offspring, excluding any unaffected
offspring, we see a stronger tendency towards higher risk scores
for the unaffected parents compared with controls (P= 0.03, data
not shown). However, the transmission of risk variants from
parents to offspring can deviate from the average 50% transmis-
sion rate per parent and this could lead to offspring with risk
scores that exceed the parents' average risk score. We analyzed
the transmission of risk scores from parents to offspring in our
families and found that the ratio of observed risk score to
expected risk score is higher in IBD-affected offspring than in
unaffected offspring (Figure 2e).
Comparing the average risk score of affected individuals of each
family revealed that family 3 has a CD and UC risk score below the
average scores in controls. In contrast, in the other four families at
least one of the two average risk scores is high (Figure 2f).
Therefore, of the families we analyzed, family 3 seems most likely
to carry additional genetic risk factors beyond the known variants
(or haplotypes linked to them). Such genetic risk factors
could include rare variants with intermediate-to-strong effects.
The best candidate risk variant from our list of candidates for
family 3 (Table 1) is a missense mutation in the ubiquitin E3 ligase
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TRIM11 [MIM 607868], c.1240G4A (p.H414Y). This variant is novel
according to Kaviar.14 Members of the TRIM protein family have a
role in host defense and regulate the NF-κB pathway,20,21 thus we
hypothesized that TRIM11 could be involved in the IBD etiology.
We used Sanger sequencing to validate the variant’s presence in
the three affected family members and its absence in the
unaffected parent and sibling. We evaluated the functional impact
of the p.H414Y variant on the TRIM11 protein product by
computational and experimental analysis.
Analysis of the function of TRIM11 p.H414Y
The TRIM11 p.H414Y mutation maps to the PRY-SPRY domain,
which is thought to mediate protein–protein interactions and
which is shared by multiple members of the TRIM protein family.21
A better-studied member of the TRIM family is TRIM20 [MIM
608107], which causes the autoinflammatory disease familial
Mediterranean fever (FMF) [MIM 134610].22,23 The most severe
disease mutations, p.M680I, p.M694I, p.M694V and p.V726A, are
located in the PRY-SPRY domain of TRIM20.24 We used protein
Figure 2. Polygenic risk scores. (a) Histograms of polygenic risk scores for CD (upper panel) and UC (lower panel) for all analyzed genomes
(38 IBD family genomes and 1,096 control genomes). (b) Density plots of CD and UC polygenic risk scores for affected individuals versus
controls (P values derived from one-sided Wilcoxon rank-sum test). (c) ROC for the discrimination between cases and controls using the
polygenic risk scores, Nagelkerke pseudo R2 indicates explained variance by polygenic risk scores. (d) Comparison of CD (upper panel) and UC
(lower panel) polygenic risk scores in familial IBD cases, unaffected family members, and controls (P value derived from one-sided Wilcoxon
rank-sum test). (e) Ratio of transmission of CD and UC polygenic risk score from parents to affected offspring and unaffected offspring (dotted
line indicates expected average transmission ratio of 1, P values derived from two-sided t-test). (f) Family-wise comparison of polygenic risk
scores of affected family members versus controls (dotted line indicates average polygenic risk score in controls). AUC, area under the curve;
CD, Crohn's disease; IBD, inflammatory bowel disease; ROC, receiver operator characteristic analysis; UC, ulcerative colitis.
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modeling to estimate the impact of TRIM11 p.H414Y and the
pathogenic TRIM20 mutations on folding and stability of the
PRY-SPRY domain. Our results indicate that mutation to Y at the
TRIM11 p.H414-corresponding position in TRIM20 is potentially
destabilizing, although the effect is presumably weak with a ΔΔG
of 4.22 kcal/mol. Values exceeding 3 kcal/mol suggest reduced
stability,25 but many potential mutations in the PRY-SPRY domain
have ΔΔG values of 50 kcal/mol or higher (Supplementary Figure
1). The TRIM20 pathogenic mutations have small negative ΔΔG
values indicating no or a weakly stabilizing effect (Supplementary
Table 2). Interestingly, all these mutations affect residues at the
surface of the structure of the PRY-SPRY domain (Figure 3a). These
findings suggest that, similar to the TRIM20 pathogenic mutations,
TRIM11 p.H414Y may affect protein–protein interactions rather
than protein folding and stability.
Residue p.414 of TRIM11 is moderately conserved among
mammalian species, but poorly conserved among other TRIM
family members. This suggests that this position may be important
for the specificity of TRIM11 interactions with other proteins
(Supplementary Figures 2 and 3).
We next used luciferase reporter assays to test the effect of the
TRIM11 p.H414Y mutation experimentally. The assays were
designed to report activity of the NF-κB1 promoter and
activity of the interferon signaling response element from the
promoter of interferon-induced protein with tetratricopeptide
repeats 1. As shown in Figure 3b, expression of wild-type TRIM11
represses both NF-κB and interferon signaling; the mutant TRIM11
p.H414Y, however, has the opposite effect in that NF-κB and
interferon signaling are both induced in response to its ectopic
expression.
We further analyzed the location of TRIM11 expression using
immunostaining of murine intestinal sections. TRIM11 localizes to
the surface of intestinal villi and is specifically expressed in
enterocytes and goblet cells (Figure 3c).
DISCUSSION
We analyzed whole-genome sequences of 38 individuals from five
families with high incidence of IBD. In these families, we identified
new rare candidate risk variants, and we found an increase in CD
polygenic risk scores compared with controls. One family,
however, did not show increased polygenic risks, suggesting the
possible presence of a new rare IBD risk variant with substantial
effect size. Therefore, we further characterized the function of the
top candidate mutation in this family, TRIM11 p.H414Y. Our results
from protein modeling, conservation analysis, functional testing
and expression location indicate that TRIM11 p.H414Y is a
plausible candidate for increasing the risk for IBD.
On the basis of the observed concordance rates in monozygotic
twins, the heritability of CD was previously estimated to be up to
50%, and up to 19% for UC.10,26,27 In addition to the variability
between studies, heritability estimates represent averages for
which the underlying distributions are unknown; we are therefore
cautious in interpreting heritability inferred from twin studies as
leading to generalized insight into the genetic architectures of
complex traits.28 If we, however, assume 50% CD heritability, then
explaining 39% of the variance with the CD polygenic risk score
suggests that 78% of the expected genetic contribution in our
cohort is accounted for by the known variants. In other words, less
than a quarter of the genetic risk in families 1, 2, 4 and 5 would be
expected to be due to unknown, rare variants. It is nevertheless
Figure 3. TRIM11 candidate variant p.H414Y. (a) Molecular model of the structure of TRIM11. The arrow points at the TRIM11 p.H414Y
mutation. Other residues in sphere format indicate corresponding familial Mediterranean fever pathogenic mutations from TRIM20.
(b) Relative activity in luciferase reporter assays testing the activity of the NF-κB promoter and the interferon signaling response element
under ectopic expression of the empty vector (Vector), vector expressing wild-type TRIM11 (WT), and vector expressing p.H414Y mutated
TRIM11 (H414Y). (c) Immunostaining of TRIM11 in murine intestinal sections, original magnification: left (×200), right (×400). ISRE, interferon
signaling response element; NF-κB, nuclear factor of kappa light chain enhancer in B-cells.
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possible that the additional candidate variants we identified (but
did not evaluate functionally) may have a role in IBD development
in these families. For UC, the polygenic risk scores accounted for
only a very small amount of the variance in these families (1%).
One reason for this may be that we did not have as many UC
patients as CD patients in our cohort and only one of the five
families was mainly affected with UC. In general, the etiology of
UC appears more complex than that of CD and may involve more
contribution from non-genetic factors; the genetic associations
with UC are usually smaller than for CD and the twin concordance
rates are also much smaller. Therefore, explaining disease risk with
a polygenic risk score based on known genetic associations is less
feasible for UC than for CD.
The study by Jostins et al.,7 that identified the loci and odds
ratios we used to compute the polygenic risk scores, reported that
these loci explained 13.6% of the CD variance in their cohort. Our
value of the explained variance for CD, 39%, is substantially higher.
One possible reason for our elevated explained CD variance is that
IBD patients from highly affected families may have higher
polygenic risk than sporadic IBD cases (and the majority of IBD
patients recruited for GWAS are sporadic cases). We suspect that
the loci contributing to the high polygenic risk scores are the main
driver for the high disease burden in the families we analyzed. The
accumulation of the risk may be of a stochastic nature, in part
driven by the increased risk scores in both parents and in part
driven by the higher than average transmission rate of common
risk variants from the parents to the affected children.
We identified TRIM11 p.H414Y as a risk candidate that appears
to have a role in IBD susceptibility in family 3. TRIM proteins are
members of the RING family of ubiquitin E3 ligases and have been
implicated in the regulation of innate immune signaling, including
the NF-κB pathway, in which TRIM-mediated ubiquitination has
been shown at several steps in the pathway.20,29 Mutations in
TRIM20, better known as MEFV, can cause the autoinflammatory
disease FMF in a recessive or dominant fashion.22,23 Interestingly,
IBD-like symptoms have been observed in FMF patients and
TRIM20 mutations show association with IBD in populations with a
high rate of TRIM20 mutations and FMF.30–32 The majority of the
pathogenic FMF mutations are located in the PRY-SPRY domain of
TRIM20, which is also the location of p.H414Y in TRIM11. Our
protein modeling analyses suggest that, similar to known TRIM20
mutations, TRIM11 p.H414Y affects the protein surface structure
rather than protein stability and may therefore impact
protein–protein interactions. The function of TRIM11 is not
well understood but recently TRIM11 was reported to inhibit the
TANK-binding kinase-1 (TBK1) via protein–protein interaction that
does not involve ubiquitination.33 TBK1 is part of the virus-sensing
signaling cascade and induces NF-κB and interferon signaling.34,35
Our reporter assays showed the expected decrease in NF-κB and
interferon signaling when wild-type TRIM11 was ectopically
expressed. The observed induction of NF-κB and interferon
signaling after ectopic expression of mutant TRIM11 p.H414Y
could indicate a gain-of-function effect. It has been shown that
TRIM11 does not directly inhibit the kinase activity of TBK1 so it is
possible that instead the interaction of TBK1 with other activating
or inhibiting molecules is altered by TRIM11 binding.33 We
therefore hypothesize that the p.H414Y mutation might interfere
with the inhibitory effect of TRIM11 on TBK1 and instead induces
TBK1, leading to a stronger inflammatory signaling in response to
viruses in the gut. Several components of the NF-κB signaling
pathway have been associated with IBD before.7
We conclude from our results that the genomic architecture of
familial IBD can involve both common and rare variant
components. Common variants with small effect sizes, as have
been identified by GWAS, appear to be sufficient to account for
disease burden in many but not all families. In at least one family,
we identified a rare variant plausibly contributing to IBD on the
background of low polygenic risk. From our small study, we can
neither confidently derive what fraction of families will fit each of
the two models, nor what effect sizes rare variants may have in
IBD. Large-effect rare variants may not be a typical driver for high
incidence of IBD within families as (i) early genetic studies of IBD
that used linkage analysis in families found, in comparison to
monogenetic diseases, only modest linkage peaks, and no
high-penetrance variants were identified in the linkage
regions;36 (ii) deep resequencing of IBD GWAS loci did not reveal
risk variants with odds ratios higher than 4.5;8,37 and (iii) rare
large-effect variants are rather a hallmark of Mendelian diseases
with early (childhood) onset38,39 whereas IBD has a late onset,
usually in adolescence or early adulthood. The only context in
which highly penetrant variants have been found to cause
monogenic forms of IBD is in severe very-early-onset IBD; it has
been suggested that, given the distinct genetic and phenotypic
characteristics, very-early-onset IBD may, in fact, represent a new
disease entity that is different from classical IBD.40,41 The families
in this study do not fall into the very-early-onset IBD category.
To determine the effect sizes and disease risk contribution of
rare variants such as the TRIM11 p.H414Y mutation, it will be
necessary to study large cohorts of IBD cases and controls or
families and use high-resolution approaches like WGS. We need
more WGS studies of highly affected families to determine
whether the results from our survey of five families will generalize
to larger sets of families from many populations. In the future, we
will not only need to include rare risk variants but also
environmental factors in our risk models to predict disease risk
with a level of accuracy that is clinically useful.
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